1,721,072 research outputs found
The effect of a paracetamol and morphine combination on dynorphin A levels in the rat brain
No full textThe purpose of this study was to find out whether the combination of inactive doses of paracetamol (PARA) and morphine was able to change dynorphin (DYN) A levels, evaluated by radioimmunoassay, and whether naloxone or [(-)-2-(3 furylmethyl)-normetazocine] (MR 2266), a κ-opioid antagonist, modifies or prevents the activity of this combination on nociception and on DYN levels. The work was suggested by our previous findings which demonstrated that inactive doses of PARA and morphine, when given in combination, share an antinociceptive effect, and that PARA, at antinociceptive doses, decreases DYN levels in the frontal cortex, thus indicating a selective action within the CNS. Our present results demonstrate that the combination of inactive doses of PARA (100 mg/kg) and morphine (3 mg/kg) is just as effective in decreasing the levels of DYN A as full antinociceptive doses of PARA or morphine alone in the frontal cortex of the rat. The values, expressed in pmol/g tissue, were: control = 2.83 ± 0.20; paracetamol (100) = 2.60 ± 0.23; morphine (3) = 2.73 ± 0.24; paracetamol + morphine = 1.34 + 0.16 (P < 0.05). The decrease was partially antagonised by MR 2266, but not by naloxone, suggesting that the activity of PARA and morphine in combination on DYN A levels could be mediated, at least in part, through κ-receptors, although other systems may be involved. On the other hand, both naloxone and MR 2266 prevented the antinociceptive effect of the combination in the hot plate test. All our experimental data suggest that PARA and morphine in combination exert their antinociceptive effect through the opioidergic system, which in turn may cause a decrease in DYN levels in the CNS of the rat. © 2001 Elsevier Science Inc
The effect of paracetamol on nociception and dynorphin A levels in the rat brain
No full textMale Wistar rats were administered with naloxone (1 mg/kg i.p.) or MR 2266 (5 mg/kg i.p) 15 min before paracetamol (400 mg/kg i.p.) treatment and the pain threshold was evaluated. Rats were subjected to the hot-plate and formalin tests and immunoreactive dynorphin A (ir-dynorphin A) levels were measured in the hypothalamus, hippocampus, striatum, brainstem, frontal and parietal-temporal cortex by radioimmunoassay. Pretreatment with naloxone abolished paracetamol antinociceptive activity both in hot-plate and in the first phase, but not in the second phase of the formalin test, while MR 2266 pretreatment was able to antagonise paracetamol effect either in the hot-plate test or in both phases of the formalin test. Among different brain areas investigated paracetamol significantly decreased ir-dynorphin A levels only in the frontal cortex. MR 2266 but not naloxone reversed the decrease in ir-dynorphin A levels elicited by paracetamol. Paracetamol seems to exert its antinociceptive effect also through the opioidergic sistem modulating dynorphin release in the central nervous system (CNS) of the rat, as suggested by the decrease in the peptide levels. © 2001 Harcourt Publishers Ltd
Limbic seizures increase pronociceptin mRNA levels in the thalamic reticular nucleus
No full textWe studied pronociceptin gene expression following limbic seizures. Northern blot anaysis revealed increased pronociceptin mRNA levels in the thalamus (but not in the hippocampus) 3-24 after kainate administration, with maximal effect (2-fold increase over basal levels) reached at 6h. No variation in pronociceptin mRNA levels was observed 1-6 h after a stimulus- evoked kindled seizure. Carrageenan failed to affect pronociceptin gene expression in the thalamus, indicating that pain and/or acute stress do not account for kainate effects. In situ hybridization revealed that kainate evokes a dramatic (4-fold) increase in pronociceptin mRNA levels over the thalamic reticular nucleus. Kindled seizures evoked only a small, non- significant increase in pronociceptin gene expression over the dentate gyrus of the hippocampus
Modulation of proorphaninFQ/N gene expression by morphine in the rat mesocorticolimbic system
No full textWe studied the effects of acute and chronic morphine treatment on proorphaninFQ/N (proOFQ/N) gene expression in the mesocorticolimbic system, known to be a reward-relevant area, of the rat CNS. Northern blot analysis revealed that a single injection of morphine 10 mg/kg i.p. increased proOFQ/N mRNA levels in nucleus accumbens, temporo-parietal cortex and in striatum. The chronic administration of the opiate caused a significant increase of proOFQ/N mRNA levels in the ventral tegmental area and a decrease in the striatum and in the nucleus accumbens. No changes were observed in the prefrontal cortex. These data indicate for the first time that morphine alters proOFQ/N gene expression in mesocorticolimbic areas, supporting the direct interaction between the opioid and OFQ/N systems and the OFQ/N involvement in morphine-rewarding mechanisms. © 2002 Lippincott Williams & Wilkins
Supraspinal and spinal effects of [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1-13)-NH2 on nociception in the rat
No full textA new derivative of the neuropeptide nociceptin (NC) has recently been developed. This molecule, the pseudopeptide [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1-13)-NH2 was found to antagonize NC inhibitory effects in peripheral smooth muscle preparations in vitro. However, contrasting results have appeared as regards its pharmacodynamic profile in the CNS. Here, we investigated the pseudopeptide effects, in vivo, on nociceptive responses in the rat. [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1-13)-NH2 was administered intracerebroventricularly (i.c.v.) or intrathecally (i.t.) (alone or in combination with NC), and tail-flick latencies (TFL) to radiant heat were assessed. I.c.v. [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1-13)-NH2 (1-10 nmol/rat) caused a short-lasting decrease (5 min) of TFL and did not antagonize the threshold lowering effect of i.c.v. NC (1 nmol/rat). At the spinal level, the i.t. administration (0.2-10 nmol/rat) of [Phe1Ψ(CH2-NH)Gly2]-nociceptin(1-13)-NH2 produced a dose-dependent and long-lasting antinociceptive effect that was not modified by the administration of a high dose (30 nmol/rat i.t.) of the opioid antagonist naloxone. The i.t. co-administration of the pseudopeptide (10 nmol/rat) did not block the antinociceptive effect of i.t. NC (10 nmol/rat). These data indicate that the pseudopeptide behaves as an NC agonist at supraspinal and spinal levels in the rat tail-flick test of nociception. These different profiles in the periphery and the CNS could suggest differences between central and peripheral NC receptor/s and provide a basis for further development of antagonist molecules suitable for their characterization
Regulation of the genes encoding the ppN/OFQ and NOP receptor
No full textOver the years, the ability of N/OFQ-NOP receptor system in modulating several physiological functions, including the release of neurotransmitters, anxiety-like behavior responses, modulation of the reward circuitry, inflammatory signaling, nociception, and motor function, has been examined in several brain regions and at spinal level. This chapter collects information related to the genes encoding the ppN/OFQ and NOP receptor, their regulation, and relative transcriptional control mechanisms. Furthermore, genetic manipulations, polymorphisms, and epigenetic alterations associated with different pathological conditions are discussed. The evidence here collected indicates that the study of ppN/OFQ and NOP receptor gene expression may offer novel opportunities in the field of personalized therapies and highlights this system as a good “druggable target” for different pathological conditions
Alterations of CREB and DARPP-32 phosphorylation following cocaine and monoaminergic uptake inhibitors
No full textThe cAMP response element-binding protein (CREB) is a transcription factor that can contribute to drug-induced changes in gene expression. It is well known that the dopamine and cAMP-regulated phosphoprotein (DARPP-32), via activation, is converted into a potent inhibitor of protein phosphatase-1 (PP-1), which regulates the activity of CREB. We previously reported that the continuous infusion of cocaine for 7 days produced a significant increase in prodynorphin mRNA in the rat caudate putamen and we also studied the role of the different monoamines in these cocaine effects. Since multiple cAMP response element (CRE) sequences are present on the prodynorphin gene promoter, the aim of our study was to investigate the effects of cocaine and monoaminergic uptake inhibitors on CREB and DARPP-32 phosphorylation and moreover the possible correlation with the changes already observed on prodynorphin gene expression. Here we investigated the alterations on phospho-Ser133 CREB, phospho-Thr34 DARPP-32 and phospho-Thr75 DARPP-32 induced by continuous infusions of cocaine, GBR12909, fluoxetine and nisoxetine. A significant decrease in both phospho-CREB at Ser133 and phospho-DARPP-32 at Thr34 in the rat caudate putamen was produced by cocaine, GBR 12909, fluoxetine or nisoxetine. No alterations were observed on phospho-Thr75 DARPP-32 levels. We hypothesize that the decrease in phospho-Thr34 DARPP-32 could evoke an increase in PP-1 activity which is responsible for the reduction of CREB activation. These effects could in turn elicit the reduction in the transcriptional cascade of the prodynorphin gene in the caudate putamen, observed following chronic fluoxetine and nisoxetine. On the other hand, these mechanisms do not seem to be involved in cocaine- or GBR 12909-induced effects.[...
Limbic seizures increase pronociceptin mRNA levels in the thalamic reticular nucleus
No full textWe studied pronociceptin gene expression following limbic seizures. Northern blot anaysis revealed increased pronociceptin mRNA levels in the thalamus (but not in the hippocampus) 3-24 after kainate administration, with maximal effect (2-fold increase over basal levels) reached at 6h. No variation in pronociceptin mRNA levels was observed 1-6 h after a stimulus- evoked kindled seizure. Carrageenan failed to affect pronociceptin gene expression in the thalamus, indicating that pain and/or acute stress do not account for kainate effects. In situ hybridization revealed that kainate evokes a dramatic (4-fold) increase in pronociceptin mRNA levels over the thalamic reticular nucleus. Kindled seizures evoked only a small, non- significant increase in pronociceptin gene expression over the dentate gyrus of the hippocampus
Regulation of dynorphin gene expression by kappa-opioid agonist treatment
No full textThe effects of K-opioid agonist treatment on prodynorphin mRNA expression in the rat brain were studied. Rats were treated with the selective kappa-opioid agonist U-69593 or vehicle for 5 days and prodynorphin mRNA was measured on day 8 (3 days after the last injection) or 22 (17 days after the last injection). On day 8 prodynorphin mRNA was increased in the hypothalamus and decreased in the striatum, frontal cortex, and hippocampus of rats treated with U-69593. On day 22, prodynorphin mRNA was increased in the hypothalamus, frontal cortex and striatum of U-69593 treated rats. These findings suggests that kappa-opioid receptor agonist treatment has long-term, continually changing effects on prodynorphin mRNA expression
- …
